Value Of Genetic Information Research Articles

Genetic Testing to Signal Quality in Beef Cattle: Bayesian Methods for Optimal Sample Size

AbstractGenetic testing is one way that feeder cattle producers can credibly signal quality to buyers. However, quality signaling in the presence of asymmetric information typically requires paying measurement costs. Given that previous research has indicated that the value of genetic information is generally not enough to offset the current cost of testing, we evaluate random sampling as a strategy to reduce the overall cost of testing. An economic approach to sample size determination is introduced utilizing a Bayesian decision theoretic framework to balance the expected costs and benefits of sampling. Data from 101 pens (2,796 animals) of commercially‐fed cattle are used to empirically evaluate optimal sampling. Assuming profit is linear (nonlinear) in genetic information, results indicate that at the baseline parameter values an optimal sample size of nine (five) out of 100 animals generates returns from sampling of $7.87/head ($5.96/head). Sensitivity analyses indicate that the degree of asymmetric information (absolute difference between seller and buyer prior expectations of quality) is the major driver of the overall results. The results provide strong evidence that random sampling generates benefits that far exceed the costs.

Abstract 1303: A genome-wide association study of prostate cancer in Latinos

Abstract Recent studies estimate that individuals of African or Latin American ancestry represent less than 4% of samples analyzed to date in genome-wide association studies. The clinical value of genetic information in guiding personalized medicine in populations of non-European ancestry will require additional discovery and risk locus characterization efforts in these populations. Here, we performed a genome-wide association study (GWAS) meta-analysis of prostate cancer in Latino men to search for risk loci that may be important in this population. We combined GWAS data for 1034 cases and 1046 controls genotyped with the Illumina 660 Beadarray with GWAS data for 1235 cases and 1053 controls genotyped with the Illumina Oncoarray as part of the ELLIPSE U19 GAME-ON Consortium. A total of ~11 million genotyped and imputed SNPs of ≥1% frequency were tested for association with prostate cancer risk in logistic regression models controlling for age, study and genetic ancestry. Genome-wide significant associations were observed with 24 variants all located at 8q24 (128.484-128.548), and which capture the first reported prostate cancer susceptibility locus in ‘region 1’ of 8q24. The most significant association genome-wide was with SNP rs7824776 (risk allele frequency, 0.35; OR=1.69, p=3.4x10-11). No novel genome-wide significant associations were noted outside of 8q24. We observed a high degree of generalizability of known prostate cancer risk loci, with 78 (76%) of the 103 known risk variants having effects that were directionally consistent in their association with prostate cancer risk as previously reported, of which 31 (30%) were statistically significant with p < 0.05. In addition to these findings from the largest GWAS of prostate cancer in Latinos conducted to date, we will also present the results investigating effect heterogeneity by local ancestry (i.e. proportion Native American vs. European). In addition, we will present a comparison of polygenic risk models between Latinos, African Africans and men of European ancestry that incorporate the known risk loci to better understand how genetic risk tracks with population differences in prostate cancer incidence. Citation Format: Hannah Hopp, Sue Ingles, Chad Huff, Xin Sheng, Brandi Weaver, Mariana Stern, Sara Strom, Ian Thompson, David Conti, Christopher A. Haiman. A genome-wide association study of prostate cancer in Latinos [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 1303. doi:10.1158/1538-7445.AM2017-1303

Correction: The Value of Genetic Information for Diabetes Risk Prediction – Differences According to Sex, Age, Family History and Obesity

Correction: The Value of Genetic Information for Diabetes Risk Prediction – Differences According to Sex, Age, Family History and Obesity

Opportunities in the Economics of Personalized Health Care and Prevention.

Personalized medicine is best viewed from a broad perspective of trying to use information about a patient to improve care. While "personalized medicine" often emphasizes the value of genetic information, traditional clinical approaches to personalizing care based on patient phenotype, provider and system-level factors should not be neglected. As these diverse approaches to personalization are examined, tools such as cost-effectiveness analysis can provide important insights into the value of these approaches, strategies for their implementation and dissemination, and priorities for future research. Such analyses are likely to be most insightful if they recognize that patient and provider behaviors are essential determinants of the value of treatments and that patient factors in particular may have large effects on the value of treatments and the need for interventions to improve decision making. These comments suggest three major areas of opportunity for economic analyses of personalized medicine: (1) traditional clinical approaches to personalized medicine, (2) multi-perspective studies of the benefits and costs of personalized medicine, and (3) the role of behavior in the value of personalized medicine.

12 Fingers or One, it's How You Play?

For quite some time, debate has raged about what the human race can and should do with its knowledge of genetics. We are now nearly 60 years removed from the work of Watson and Crick who determined the structure of deoxyribonucleic acid (DNA), yet our opinions as how best to employ scientific knowledge of the human genome, remain as diverse and polarised as ever. Human judgment is often shaped and coloured by popular media and culture, so it should come as no surprise that box office movies such as Gattaca (1997) continue to play a role in informing public opinion on genetics. In order to perform well at the box office, movies such as Gattaca take great liberty in sensationalising (and even distorting) the implications that may result from genetic screening and testing. If the public’s opinion on human genetics is strongly derived from the box office and popular media, then it is no wonder that the discourse on human genetics is couched in the polar parlances of future utopias or future dystopias. When legislating in an area like genetic discrimination in the workforce, we must be mindful of not overplaying the causal link between genetic predisposition towards a disability and an employee’s ability to perform the inherent requirements of their job. Genetic information is ultimately about people, it is not about genes. Genetic discrimination is ultimately about actions, it is not about the intrinsic value of genetic information.

Great expectations: views of genetic research participants regarding current and future genetic studies

PurposeRecruitment of prior participants in genetic research is one strategy suggested to maximize efficient use of research dollars in gene-environment studies. We explored attitudes toward genetic research participation among people in a case-control genetic epidemiology study of colon cancer, the North Carolina Colorectal Cancer Study (NCCCS). MethodsQuantitative and qualitative cross-sectional analysis of 801 NCCCS participants. ResultsParticipants were “very positive” (63%) or “positive” (32%) about genetic research, and “very likely” (49%) or “somewhat likely” (40%) to participate in future genetic research. Variables significantly associated with feeling “very positive” were white race, more education, nonreligious, hearing “a lot” about genetic research, and two measures of trust in medical research. Except for race and education, the same variables were significantly associated with being “very likely” to participate in future studies. Qualitatively, “good things” for self and family included discovering causes and cures for cancer, and the value of genetic information. Many could not list “bad things”; those who did mentioned anxiety, “knowing too much,” losing confidentiality, or abuse of information. ConclusionsDespite very positive attitudes of these participants toward genetic research, there is significant variation based on participant characteristics. These findings should encourage and caution researchers attempting to recruit prior participants into genetic studies.

Molecular diagnosis of primary hyperparathyroidism in familial cancer syndromes

In the last few years, causative genes have been identified for most of the familial hyperparathyroidism conditions. Germline mutations in the tumour suppressors multiple endocrine neoplasia type 1 (MEN1) and hyperparathyroidism 2 (HRPT2) provide a molecular diagnosis of multiple endocrine neoplasia type 1 and hyperparathyroidism jaw tumour syndrome, respectively. Germline mutations in the proto-oncogene RET (rearranged during transfection) provide a molecular diagnosis of multiple endocrine neoplasia type 2. Germline mutations of both MEN1 and, less frequently HRPT2, have been found in familial isolated hyperparathyroidism. A molecular diagnosis can now be incorporated into the management of patients with these conditions, however, the ease of diagnostics and value of genetic information in the context of clinical screening and early surgical intervention varies between these disorders. This review focuses on familial hyperparathyroidism and its known causative genes in the setting of neoplastic syndromes, with particular discussion of recent developments in the molecular diagnosis of parathyroid carcinoma.

US public has mixed views on value of genetic information

US public has mixed views on value of genetic information

The value of genetic information in the life insurance market

This paper analyzes the effects of additional information in a life insurance market under adverse selection. Individuals have an incentive to acquire information about their risk type if their informational status cannot be observed by insurers. In aggregate, however, the existence of a testing opportunity has an effect on the equilibrium premium. We describe the conditions under which, from an ex ante standpoint, all individuals gain, all lose or in which some gain and some lose from the existence of the test.

Genetic information and investment in human capital

In a game of incomplete information we analyze the consequences of giving an employer access to imperfect genetic information about his employees. The employer chooses whether to invest in the employee and the employee chooses a life style. We derive the condition for markets of information services to exist and the conditions for when it is beneficial to the various parties. In one specification of the game, the mere introduction of the information service may change the employee's choice of health behavior, which means that the value of genetic information may be negative to the employer.